gammaCore
Commercial- Indications
- Migraine, Cluster headache, Hemicrania continua
Company intelligence / Profile preview
electroCore has commercialized multiple non-invasive neuromodulation devices targeting the vagus and peripheral nerves. Its lead product gammaCore treats migraine and cluster headache with established clinical efficacy. Truvaga addresses general wellness including stress reduction and sleep improvement. The company recently acquired the Quell wearable device for fibromyalgia from NeuroMetrix to expand its portfolio into chronic pain management. Clinical data support efficacy of these devices across several neurological and pain-related conditions.
2 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on electroCore.